E0509 - Weight Loss Outcomes With and Without Diabetes in Patients With NAFLD in a Specialty Fatty Liver Disease Program

Tuesday, October 25, 2022

3:00 PM – 5:00 PM ET

Location: Crown Ballroom

Has Audio

Presenting Author(s)

Ysabel C. Ilagan-Ying, MD

Yale University School of Medicine
New Haven, CT

Ysabel C. Ilagan-Ying, MD, Kailyn Valido, BS, Rachel Jaber Chehayeb, BS, Bryan Bollinger, BA, Wajahat Mehal, MD, PhD, Albert Do, MD, MPH
Yale University School of Medicine, New Haven, CT

Introduction: Nonalcoholic fatty liver disease (NAFLD) is strongly linked to insulin resistance. As a result, type 2 diabetes mellitus (T2DM) is commonly comorbid in NAFLD and can increase morbidity and reduce weight loss treatment efficacy. We studied weight loss in adult NAFLD patients without and with T2DM (NAFLD-DM) receiving care in the Yale Fatty Liver Disease Program (YFLDP), which focuses on the integration of medical weight management treatments and hepatology care.

Methods: We analyzed retrospective data for adult patients with diagnostic codes for NAFLD and T2DM with complete data on body weight and at least one clinic visit between 5/23/2018 and 5/02/2022. Patients were categorized as NAFLD or NAFLD-DM. Total body weight loss (WL) was quantified using 0%, 5%, and 10% thresholds. Between NAFLD and NAFLD-DM groups, we compared total body weight loss (WL) and across WL threshold groups, we also compared initial weights, follow-up time, medical interventions received, and results of non-invasive liver fibrosis tests.

Results: There were 933 patients with NAFLD, of whom 463 (49.6%) had NAFLD-DM. After a median follow-up of 7.7 months, 632 (67.7%) of all patients achieved any weight loss. Significantly more patients with NAFLD-DM lost weight compared to NAFLD alone (73.9 vs 61.7%, p< 0.0001). Weight loss between NAFLD and NAFLD-DM groups varied, respectively: 0-5% WL: 34.7% vs. 34.8% (p=0.98); 5-10% WL: 13.2% vs. 19.2% (p=0.01), >10% WL: 13.8% vs. 19.9% (p=0.01). Compared to those not losing weight, NAFLD and NAFLD-DM patients with >10% WL had significantly greater proportion of participation in a complete meal replacement program (Optifast®) or treatment with GLP-1 agonist semaglutide. For NAFLD and NAFLD-DM groups, there was no significant difference between initial Fibroscan stiffness or FIB-4 index and subsequent WL percentages (Table 1).

Discussion: The majority of NAFLD and NAFLD-DM patients receiving care in a specialty clinic incorporating medical weight management with liver care successfully achieved weight loss in a relatively short period. Patients with NAFLD-DM did not have significantly worse outcomes with weight loss, and NAFLD-T2DM patients lost more weight than NAFLD patients. These findings suggest that an integrative care liver clinic with concurrent weight management care can help patients improve metabolic diseases associated with NAFLD, particularly T2DM, and in turn improve liver-related outcomes.

Figure: Figure 1. Comparison of Clinic Interventions between No Weight Loss (WL) versus >10% WL patients with NAFLD (top panel, a) and NAFLD-DM (bottom panel, b).
*Statistically significant p-values using chi-square analysis, which can be found in Table 1.

	NAFLD (n=470 patients)			NAFLD-DM (n=463 patients)
Patient Categories n (%)	No WL 180 (38.3)	>10% WL 65 (13.8)	p	No WL 121 (26.1)	>10% WL 92 (19.9)	p
Clinic Interventions n (%)
Nutrition Consultation	80 (44.4)	31 (47.7)	0.652	58 (47.9)	40 (43.5)	0.518
OPTIFAST^® Program	4 (2.2)	5 (7.7)	0.045	2 (1.7)	8 (8.7)	0.016
Naltrexone/Buproprion	6 (3.3)	5 (7.7)	0.146	16 (13.2)	6 (6.5)	0.111
Semaglutide	15 (8.3)	17 (26.2)	< 0.001	30 (24.8)	37 (40.2)	0.016
Liraglutide	11 (6.1)	7 (10.8)	0.217	21 (17.4)	7 (7.6)	0.037
Phentermine	9 (5.0)	10 (15.4)	0.007	15 (12.4)	17 (18.5)	0.219
Bariatric Surgery Referral	13 (7.2)	5 (7.7)	0.901	21 (17.4)	31 (33.7)	0.006
Health Outcomes mean (SD)
Follow-Up Time, days	256 (276.5)	422 (296.8)	< 0.001	271 (280.2)	403 (297.3)	0.001
Initial FibroScan^® Stiffness, kPa	8.63 (6.72)	13.18 (14.01)	0.663	13.18 (14.01)	12.48 (12.49)	0.701
Initial FIB-4 Score	1.32 (1.13)	1.70 (1.98)	0.068	1.70 (1.98)	1.83 (2.11)	0.648
Initial Weight, kg	93.82 (25.45)	102.20 (24.90)	0.015	102.20 (24.90)	109.61 (25.07)	0.056

Table: Table 1. Characteristics of and Clinical Interventions for NAFLD and NAFLD-DM Patients in the Yale Fatty Liver Disease Program (YFLDP). There was a significantly lower proportion of patients with NAFLD compared to NAFLD-DM who were able to achieve > 10% Weight Loss (13.8 vs. 19.9, p=0.014), and significantly more NAFLD patients compared to NAFLD-DM who did not achieve any weight loss (38.3 vs. 26.1, p<0.001). *Denotes statistical significance p<0.05. WL = Weight Loss.

Disclosures:

Ysabel Ilagan-Ying indicated no relevant financial relationships.

Kailyn Valido indicated no relevant financial relationships.

Rachel Jaber Chehayeb indicated no relevant financial relationships.

Bryan Bollinger indicated no relevant financial relationships.

Wajahat Mehal indicated no relevant financial relationships.

Albert Do indicated no relevant financial relationships.

Ysabel C. Ilagan-Ying, MD, Kailyn Valido, BS, Rachel Jaber Chehayeb, BS, Bryan Bollinger, BA, Wajahat Mehal, MD, PhD, Albert Do, MD, MPH. E0509 - Weight Loss Outcomes With and Without Diabetes in Patients With NAFLD in a Specialty Fatty Liver Disease Program, ACG 2022 Annual Scientific Meeting Abstracts. Charlotte, NC: American College of Gastroenterology.